<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576340</url>
  </required_header>
  <id_info>
    <org_study_id>ob002</org_study_id>
    <nct_id>NCT02576340</nct_id>
  </id_info>
  <brief_title>Spasmolytic in Upper Gastrointestinal Endoscopy</brief_title>
  <official_title>Spasmolytic (Otilonium Bromide) Use in Upper Gastrointestinal Endoscopy: Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konya Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konya Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Upper gastrointestinal system endoscopy is widely used for diagnostic approach. To increase
      the tolerability and compliance of the patient, sedation is applied. There are many studies
      showing that sedation increases the patient compliance and the tolerability. However,
      spasmolytic use in GE has not been evaluated yet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>motility</measure>
    <time_frame>3 months</time_frame>
    <description>decrease in motility during the procedure (number of peristaltic moves in a minute)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient tolerance</measure>
    <time_frame>3 months</time_frame>
    <description>patient tolerance will be determined by questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Gastroscopy</condition>
  <arm_group>
    <arm_group_label>study</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drug was administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no drug administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>otilonium bromide</intervention_name>
    <description>otilonium bromide was administered before the procedure</description>
    <arm_group_label>study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no hypersensitivity to the agent.

        Exclusion Criteria:

          -  Emergent cases,the cases with low mental compatibility and pregnant women were
             excluded from the study. Moreover, the procedures under sedation, cases with disorders
             decreasing the intestinal motility like hypothyroidism and diabetes were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konya Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>barış sevinç</investigator_full_name>
    <investigator_title>M. D.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Parasympatholytics</mesh_term>
    <mesh_term>Octylonium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

